| Date | Title | Description |
| 20.05.2026 | Shyld AI Secures $13.4M, Unleashes Agentic AI for Healthcare Transformation | Shyld AI secured a significant $13.4M in seed funding, marking a pivotal moment for healthcare AI innovation. The company pioneers active intelligence, deploying autonomous physical agents. These advanced systems are revolutionizing hospita... |
| 18.05.2026 | Shyld AI Raises $13.4M in Seed Funding | Shyld AI, a Sunnyvale, CA-based healthcare technology company developing active intelligence solutions for healthcare facilities, raised $13.4M in Seed funding.
The round was led by Aulis Capital.
The company intends to use the funds to acc... |
| 14.05.2026 | Shyld AI Secures $13.4M to Scale Agentic AI and Autonomous Disinfection Across U.S. Health Systems | What You Should Know
Shyld AI has closed a $13.4M seed round led by Aulis Capital, marking one of the largest early-stage rounds in the healthcare AI sector.
The company is moving beyond “passive” ambient AI to Active Intelligence, deployin... |
| 11.01.2026 | EpiBiologics Secures $107M Series B, Propelling Precision Protein Degradation for Cancer and Immunity | EpiBiologics closed a $107 million Series B. This investment accelerates its EpiTAC platform. The platform develops tissue-selective extracellular protein degraders. These target disease-driving membrane and soluble proteins. Lead candidate... |
| 10.01.2026 | EpiBiologics: $107 Million Series B Raised To Advance Tissue-Selective EGFR Degrader And Bispecific Antibody Pipeline | EpiBiologics announced it has closed a $107 million Series B financing to advance a pipeline of bispecific antibodies designed to selectively degrade extracellular protein targets in oncology and immunology. The round was co-led by GV and J... |
| 08.01.2026 | EpiBiologics Closes $107M Series B Funding | EpiBiologics, a San Mateo, CA-based company which specializes in tissue-selective extracellular protein degradation, raised $107M in Series B funding.
The round was co-led by GV (Google Ventures) and Johnson & Johnson, through its corpo... |
